Download PDF
Int J Angiol 2021; 30(02): 148-154
DOI: 10.1055/s-0041-1727133
Original Article

Performance of Primary Angioplasty for STEMI during the COVID-19 Outbreak

Surya Dharma
1   Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, Indonesian Cardiovascular Research Center, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
,
Iwan Dakota
2   Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
,
Isman Firdaus
2   Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
,
Siska Suridanda Danny
2   Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
,
Dian Zamroni
2   Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
,
Ardi Yudha
3   Indonesian Cardiovascular Research Center, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
,
Agus Susanto
4   Catheterization Laboratory Nurse Manager, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
,
Bambang Budi Siswanto
2   Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
› Author Affiliations Funding No external funding support.
› Further Information
   Permissions and Reprints

Abstract

There has been concern whether the declining cases of ST-segment elevation myocardial infarction (STEMI) during the coronavirus disease 2019 (COVID-19) outbreak associate with primary angioplasty performance.

We assessed the performance of primary angioplasty in a tertiary care hospital in Jakarta, Indonesia, by comparing the door-to-device (DTD) time and thrombolysis in myocardial infarction (TIMI) flow after angioplasty between two periods of admission: during the outbreak of COVID-19 (March 1 to May 31, 2020) and before the outbreak (March 1, to May 31, 2019).

Overall, there was a relative reduction of 44% for STEMI admission during the outbreak (n = 116) compared with before the outbreak (N = 208). Compared with before the outbreak period (n = 141), STEMI patients who admitted during the outbreak and received primary angioplasty (n = 70) had similar median symptom onset-to-angioplasty center admission (360 minutes for each group), similar to radial access uptake (90 vs. 89.4%, p = 0.88) and left anterior descending infarct-related artery (54.3 vs. 58.9%, p = 0.52). The median DTD time and total ischemia time were longer (104 vs. 81 minutes, p < 0.001, and 475.5 vs. 449 minutes, p = 0.43, respectively). However, the final achievement of TIMI 3 flow was similar (87.1 vs. 87.2%), and so was the in-hospital mortality (5.7 vs. 7.8%).

During the COVID-19 outbreak, we found a longer DTD time for primary angioplasty, but the achievement of final TIMI 3 flow and in-hospital mortality were similar as compared with before the outbreak. Thus, primary angioplasty should remain the standard of care for STEMI during the COVID-19 outbreak.

Keywords

primary angioplasty - performance measures - COVID-19 outbreak

Note

There was no external funding to support this study, and this study has no relationship with any industrial company.


Disclosures

Nothing to declare.




Publication History

Article published online:
20 April 2021

© 2021. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 De Filippo O, D'Ascenzo F, Angelini F. et al. Reduced rate of hospital admissions for ACS during Covid-19 outbreak in Northern Italy. N Engl J Med 2020; 383 (01) 88-89
    CrossrefPubMedGoogle Scholar
  • 2 Metzler B, Siostrzonek P, Binder RK, Bauer A, Reinstadler SJ. Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage. Eur Heart J 2020; 41 (19) 1852-1853
    CrossrefPubMedGoogle Scholar
  • 3 Dharma S, Andriantoro H, Purnawan I. et al. Characteristics, treatment and in-hospital outcomes of patients with STEMI in a metropolitan area of a developing country: an initial report of the extended Jakarta Acute Coronary Syndrome registry. BMJ Open 2016; 6 (08) e012193 DOI: 10.1136/bmjopen-2016-012193.
    CrossrefPubMedGoogle Scholar
  • 4 Dharma S, Andriantoro H, Dakota I. et al. Organisation of reperfusion therapy for STEMI in a developing country. Open Heart 2015; 2 (01) e000240 DOI: 10.1136/openhrt-2015-000240.
    CrossrefPubMedGoogle Scholar
  • 5 Dharma S, Siswanto BB, Firdaus I. et al. Temporal trends of system of care for STEMI: insights from the Jakarta Cardiovascular Care Unit Network System. PLoS One 2014; 9 (02) e86665 DOI: 10.1371/journal.pone.0086665.
    CrossrefPubMedGoogle Scholar
  • 6 Dharma S, Sari NY, Santoso A, Sukmawan R, Rao SV. Association of plasma pentraxin 3 concentration with angiographic and clinical outcomes in patients with acute ST-segment elevation myocardial infarction treated by primary angioplasty. Catheter Cardiovasc Interv 2020; 96 (06) 1233-1239
    CrossrefPubMedGoogle Scholar
  • 7 Central Bureau of Statistics - Indonesia. 2016 statistics
    PubMed
  • 8 Jakarta Tanggap COVID-19. Dinas Kesehatan DKI Jakarta. ; [cited 2020 April 27]. Accessed March 11, 2021 from: https://corona.jakarta.go.id/id
    PubMedGoogle Scholar
  • 9 Ibanez B, James S, Agewall S. et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
    CrossrefPubMedGoogle Scholar
  • 10 O'Gara PT, Kushner FG, Ascheim DD. et al; CF/AHA Task Force. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127 (04) 529-555
    CrossrefPubMedGoogle Scholar
  • 11 Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital. Intensive Care Med 2020; 46 (06) 1111-1113
    CrossrefPubMedGoogle Scholar
  • 12 Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361 (9351): 13-20
    CrossrefPubMedGoogle Scholar
  • 13 Mahmud E, Dauerman HL, Welt FGP. et al. Management of acute myocardial infarction during the COVID-19 pandemic: a position statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). J Am Coll Cardiol 2020; 76 (11) 1375-1384
    CrossrefPubMedGoogle Scholar